Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study-Reference-Cited by-同舟云学术

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

Published:2023-07 Issue: Volume:Volume 10 Page:1195-1206
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Zhao Chenghao,Xiang Zhanwang,Li Mingan,Wang Haofan^ORCID,Liu Huan,Yan Huzheng,Huang Mingsheng^ORCID

Publisher

Informa UK Limited

Subject

General Medicine

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors

3. Hepatocellular Carcinoma

4. Hepatocellular carcinoma

5. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era;Expert Review of Molecular Diagnostics;2024-08-28

2. Comparing Health Insurance-ReimbursedFirst Line Lenvatinib and Self-paid Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma;2024-06-27

3. Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis;European Journal of Clinical Pharmacology;2024-06-22

4. Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis;Liver Cancer;2024-05-22

5. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis;Clinical and Translational Oncology;2024-04-26